Chronic Lymphocytic Leukemia

Farrukh T. Awan, John C. Byrd

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

The last decade has brought significant improvements in understanding of the biology of chronic lymphocytic leukemia (CLL) and the resultant dramatic evolution in its therapeutic landscape. This interval saw the approval of the first targeted therapy, rituximab, to an era where chemoimmunotherapy based treatments are being utilized less commonly. Additional antibodies were approved in the United States including ofatumumab and obinutuzumab, along with the small molecule inhibitors targeting the B-cell receptor and Bcl-2 pathways, ibrutinib, idelalisib, and venetoclax. Since these novel agents are now being utilized frequently, their use raises additional questions about sequencing, combination, resistance, and duration of use. In this chapter, we will discuss the historic developments in the field, and highlight the recent dramatic and major advances that have significantly improved outcomes for patients with CLL.

Original languageEnglish (US)
Title of host publicationAbeloff’s Clinical Oncology
PublisherElsevier
Pages1850-1871.e5
ISBN (Electronic)9780323476744
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • Anti-CD20 antibodies
  • B-cell receptor inhibitors
  • BCL-2 inhibitors
  • Chemoimmunotherapy
  • Chemoimmunotherapy
  • Chronic lymphocytic leukemia
  • Kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Chronic Lymphocytic Leukemia'. Together they form a unique fingerprint.

Cite this